Discussing Results From the ZUMA-1 Trial for Patients With Advanced Lymphoma

Andre Goy, MD

Andre Goy, MD, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the progress made with immunotherapy for the treatment of hematologic malignancies over the last 5 years.

Andre Goy, MD, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the progress made with immunotherapy for the treatment of hematologic malignancies over the last 5 years.

One of the most significant advancements has been CAR T-cell therapy in lymphoma. Updated data from the ZUMA-1 trial investigating axicabtagene ciloleucel were presented at the 2018 ASCO Annual Meeting, showing that in over 100 patients with heavily pretreated relapsed/refractory non-Hodgkin lymphoma, the response rate was over 80%, and over 50% of patients achieved complete response. Goy notes that at the 3-month mark, these results are also highly predictive of outcome.

At 15 months, 59% of patients are still doing well and in remission, which Goy says is quite remarkable in these patients who would otherwise have no other treatment options. Moving forward, Goy says investigators need to learn how to better predict response to this therapy.